Skip to content

Clinical trials

Dry Eye Syndromes trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Dry Eye Syndromes Phase: Not applicable Country / region: United States Clear all

132 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20041
20054
20061
20075
20086
20095
20106
20112
20124
20134
20146
20156
20165
20177
201816
20199
20206
20216
202212
20237
20247
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed99
Terminated10
Withdrawn7
Recruiting6
Unknown status6
Suspended1
Not yet recruiting1
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alcon Research14
Allergan8
University of Alabama at Birmingham7
Sight Sciences, Inc.6
Lumenis Be Ltd.5
Oculeve, Inc.5
University of Rochester5
TearScience, Inc.4
Ohio State University3
Southern California College of Optometry at Marshall B. Ketchum University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Dry Eye Syndromes132
Meibomian Gland Dysfunction34
Keratoconjunctivitis Sicca7
Sjogren's Syndrome4
Blepharitis3
Corneal Diseases3
Lacerations3
Asthenopia2
Eye Diseases2
Keratitis2

Trials

Showing 1 to 25 of 132. Each trial links to its page on Pharma Observatory.

32 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.